A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
This is a Phase 1 study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of single agent Veliparib in Japanese subjects with advanced solid tumors.
Advanced Solid Tumors
DRUG: veliparib (ABT-888)
Dose-limiting toxicities of veliparib, During the first cycle (28 days) of veliparib administration
Change in participant physical exam measurements, Blood pressure, pulse and body temperature, Approximately 1 year|Change in participant clinical lab results, Hematology, Chemistry and Urinalysis, Approximately 1 year|Number of participants with adverse events, Collect all adverse events at each visit and assess according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, Approximately 1 year|Preliminary tumor response, According to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, Participants will be followed for the duration of an expected average of 8 months.|Maximum observed plasma concentration (Cmax), Maximum observed concentration, occurring at Tmax, For 24 hours following veliparib dosing.|The time to Cmax (peak time, Tmax), The time at which maximum plasma concentration (Cmax) is observed., For 24 hours following veliparib dosing.|The area under the plasma concentration-time curve (AUC), For 24 hours following veliparib dosing.
This is a Phase 1 study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of single agent Veliparib in Japanese subjects with advanced solid tumors.